Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Enrasentan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA known ✓ | P25101 | 20/20 | 1.00 |
| ▸ | EDNRB known ✓ | P24530 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enrasentan SCHEMBL29356829 | 1.00 | EDNRA (1.00) | EDNRAEDNRB | |
| Enrasentan SCHEMBL7636324 | 1.00 | EDNRA (1.00) | EDNRAEDNRB | |
| Enrasentan SCHEMBL8206689 | 1.00 | EDNRA (1.00) | EDNRAEDNRB | |
| Enrasentan SCHEMBL1649828 | 1.00 | EDNRA (1.00) | EDNRAEDNRB | |
| Enrasentan SCHEMBL8008492 | 0.98 | EDNRA (0.97) | EDNRAEDNRB | |
| Enrasentan SCHEMBL7660593 | 0.98 | EDNRA (0.95) | EDNRAEDNRB | |
| Enrasentan SCHEMBL7610103 | 0.98 | EDNRA (0.95) | EDNRAEDNRB | |
| SCHEMBL13038489 | 0.97 | EDNRA (0.93) | EDNRAEDNRB | |
| SCHEMBL8203979 | 0.97 | EDNRA (0.93) | EDNRAEDNRB | |
| SCHEMBL7538909 | 0.96 | EDNRA (0.92) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2246062-B1 | Methods and compositions for emergency contraception using endothelin receptor antagonists | POPULATION COUNCIL INC (US) | 2012-09-26 | — | — | EP | disclosed |
| US-8173593-B2 | Methods and compositions for emergency contraception using endothelin receptor antagonists | THE POPULATION COUNCIL, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| EP-1906987-B1 | METHODS AND COMPOSITIONS FOR EMERGENCY CONTRACEPTION USING ENDOTHELIN RECEPTOR ANTAGONISTS | POPULATION COUNCIL INC (US) | 2011-01-19 | — | — | EP | disclosed |
| EP-2246062-A1 | Methods and compositions for emergency contraception using endothelin receptor antagonists | THE POPULATION COUNCIL, INC. (US) | 2010-11-03 | — | — | EP | disclosed |
| US-20090311266-A1 | Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy | BASF AKTIENGESELLSCHAFT (DE) | 2009-12-17 | — | — | US | disclosed |
| US-20090203591-A1 | Methods and compositions for emergency contraception using endothelin receptor antagonists | THE POPULATION COUNCIL, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| EP-0915699-A4 | STEREOSELECTIVE SYNTHESIS OF ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-06-25 | — | — | EP | disclosed |
| EP-0699069-B9 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2003-10-22 | — | — | EP | disclosed |
| US-6448260-B2 | 3-(2-CARBOXYMETHOXY-4-METHOXYPHENYL)-1-(3,4-METHYLENEDIOXY -PHENYL)-5-(PROP-1-YLOXY)-INDANE-2-CARBOXYLIC ACID AS AN ESPECIALLY PREFERRED COMPOUND; HYPOTENSIVE AGENTS; CARDIOVASCULAR, UROGENITAL AND RESPIRATORY DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2002-09-10 | — | — | US | disclosed |
| US-6355813-B1 | INTERMEDIATES USEFUL IN PREPARING THESE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2002-03-12 | — | — | US | disclosed |
| US-6143907-A | 3-phenyl-1-methylenedioxyphenyl-indane-2-carboxylic acid derivatives | SMITHKLINE BEECHAM CORPORATION (US) | 2000-11-07 | — | — | US | disclosed |
| US-6087389-A | TREATING CARDIOVASCULAR AND RENAL DISEASES INCLUDING HYPERTENSION, ACUTE AND CHRONIC RENAL FAILURE, CYCLOSPORINE INDUCED NEPHROTOXICITY, STROKE, CEREBROVASCULAR VASOSPASM, MYOCARDIAL ISCHEMIA, ANGINA, HEART FAILURE, ATHEROSCLEROSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-11 | — | — | US | disclosed |
| US-6080862-A | PREPARING (1S, 2R, 3S)-3-(2-HYDROXYETH-1-YLOXY)-4-METHOXYPHENYL) 1-(3,4-METHYLENEDIOXYPHENYL) 5-(PROP-1-YLOXY)INDANE-2-CARBOXYLIC ACID | SMITHKLINE BEECHAM CORPORATION (US) | 2000-06-27 | — | — | US | disclosed |
| EP-0880518-A4 | A PROCESS OF MAKING 3-PHENYL-1-METHYLENEDIOXYPHENYL-INDANE-2-CARBOXYLIC ACID DERIVATIVES | SMITHKLINE BEECHAM CORP (US) | 1999-07-28 | — | — | EP | disclosed |
| EP-0915699-A1 | STEREOSELECTIVE SYNTHESIS OF ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-05-19 | — | — | EP | disclosed |
| EP-0880518-A1 | A PROCESS OF MAKING 3-PHENYL-1-METHYLENEDIOXYPHENYL-INDANE-2-CARBOXYLIC ACID DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 1998-12-02 | — | — | EP | disclosed |
| EP-0876352-A1 | PROCESS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-11 | — | — | EP | disclosed |
| WO-1997017071-A1 | STEREOSELECTIVE SYNTHESIS OF ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-15 | — | — | WO | disclosed |
| WO-1997017330-A1 | PROCESS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-15 | — | — | WO | disclosed |
| WO-1997017342-A1 | A PROCESS OF MAKING 3-PHENYL-1-METHYLENEDIOXYPHENYL-INDANE-2-CARBOXYLIC ACID DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090311266-A1 | Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy | EDNRB, EDNRA, ITGB3 | EDNRA 2/4885EDNRB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.